B. Riley FBR analyst Mayank Mamtani raised his price target for Dicerna Pharmaceuticals to $24 from $21 following the company's Q4 results and keeps a Buy rating on the shares. Balance sheet strength allows Dicerna to focus in two liver diseases, Mamtani tells investors in a research note.
https://thefly.com/landingPageNews.php?id=2877627
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.